All In MedTech

Device Trial Radar · NCT05535361

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 15, 2023

Primary completion

Mar 1, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Eclipse Regenesis, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Children's Hospital Medical Center, Cincinnati; University of California, San Francisco; Boston Children's Hospital; Lucile Packard Children's Hospital at Stanford; Children's National Health System, Washington DC
First posted
Sep 10, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 3 months, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome

Conditions

  • Short Bowel Syndrome

Interventions

  • Distraction Enterogenesis in Adult Patients with Short Bowel SyndromeDevice

    The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 chromic sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device and procedure related adverse eventsTime frame: 4 to 6 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Lucile Packard Children's Hospital Stanford

    Palo Alto, California · Recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.